Pediatric Yellow Fever 

Updated: May 04, 2017
Author: David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS; Chief Editor: Russell W Steele, MD 



Yellow fever (YF) is a mosquito-borne infection that is caused by the YF virus and is endemic to Africa and South America. It is characterized by variable symptoms ranging from a minimal flulike illness to one that may be complicated by a toxic phase characterized by hemorrhage, hepatic failure, proteinuria, renal failure, and death.

Overall, YF reemergence has occurred since 1985, as reflected in the number of cases per year officially reported to the World Health Organization (WHO). Approximately 200,000 cases occur annually; 80-90% of those reported are from sub-Saharan Africa, primarily West Africa. YF is reemerging in South America. In addition, Aedes aegypti has repopulated large swaths of Central America, as well as the Caribbean coastal areas of the United States and most of Florida, allowing the potential reemergence of yellow fever in these areas.[1]

Supportive care is the only treatment. Mortality is 20-50%. Prevention using the live-attenuated 17D vaccine is highly efficacious.

Immediately report all suspected or confirmed cases of YF to local and state health departments, which then report immediately to the Division of Global Migration and Quarantine (1-404-498-1600) or Division of Vector-Borne Infectious Diseases (1-970-221-6400), Centers for Disease Control and Prevention (CDC). If local or state health departments cannot be reached, contact the CDC directly.


YF virus, an arbovirus, is the type species for the family Flaviviridae and is a single, positive-stranded, enveloped RNA virus. The envelope consists of a lipid bilayer containing an envelope glycoprotein and a matrix protein. The single RNA is complexed with a capsid protein. Viral strains from South America are closely related to those from West Africa. This observation supports the supposition that YF virus originated in West Africa.

The virus is transferred from the infected female mosquito’s salivary gland by means of saliva introduced into a bite wound during a blood meal. It replicates in local tissues and regional lymph nodes. The virus can then infect a feeding mosquito during the initial 3-4 days of the illness. No human-to-human transmission is known.

After the virus enters the bloodstream, hematogenous spread to the bone marrow, kidney (probable), liver (the main target), myocardium, and spleen ensues, and further replication occurs. Cerebral edema and cerebral petechial hemorrhages result from secondary factors. In the hemorrhagic diathesis that may follow, disseminated intravascular coagulation (DIC) involves decreased synthesis of coagulation factors, altered platelet function, and bleeding from the gastrointestinal (GI) mucosa and abdominal or pleural serosa.

Myocardial fiber injury occurs secondary to direct virus activity, with cloudy swelling and fatty change. Shock and death can result. Multiple organ insult involves the liver, kidneys, brain, and heart. Other consequences include hemorrhage and secondary effects of vasoactive cytokines. In an immune response, viral neutralizing antibodies are present by the end of the first week, and the virus is rapidly cleared. Immune response confers lifelong immunity. The role of immune response in pathogenesis has not yet been established.


YF is a mosquito-borne infection that is caused by the YF virus. Mosquitoes that spread the virus include A aegypti (also carries dengue and chikungunya viruses; see the image below), other Aedes species, and Haemagogus species.

This female Aedes aegypti mosquito is shown here a This female Aedes aegypti mosquito is shown here after landing on a human host. The A aegypti mosquito is a known transmitter of both dengue fever and yellow fever. A aegypti is sometimes referred to as the yellow fever mosquito. The viruses are transferred to the host when bitten by a female mosquito. Image courtesy of the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

These mosquitos are diurnal (daytime) feeders, and only females feed on blood. In humans, YF virus is transmitted to the mosquito from an ill human only during the initial 3-4 days of illness. If the female is interrupted while feeding, it may seek another host on which to feed, leading to multiple transmissions during a feeding cycle. The extrinsic incubation period (ie, the interval from the time when the mosquito is infected with YF virus to the time when the mosquito can transmit the virus to another host) is 12-21 days.

YF virus enters the ovum in the female mosquito and survives there during the dry season. Fewer than 1% of female mosquito offspring are infected. Uninfected female mosquitoes bite infected hosts, providing for viral amplification. This is essential for survival of the virus. Approximately 3-10 virions are necessary to infect a mosquito.

Mosquitoes breed in stagnant water, including rainwater in tree holes, human-made water storage vessels, used vehicle tires, and in other collections of water in and about dwellings (eg, broken coconut shells, flower vases, gutters, tin cans, and water drums). Seasonal transmission occurs, with peak transmission usually being the time of peak humidity and rainfall. In Africa, the peak season is from the middle of the rainy season to the early dry season. In South America, it is from January to March. However, transmission is not limited to the peak season.

Transmission patterns

Jungle, urban, and intermediate (savannah) cycles of transmission have been identified. In some publications, the term sylvatic cycle (from Latin silva or sylva “woods, forest”) is used as a synonym for intermediate cycle; in others, it is used as a synonym for jungle cycle.

Jungle cycle

The mosquito transmits the virus to wild nonhuman primates (or possibly an incidental human host), from which it is transmitted to another mosquito. This cycle is confined to rain forests, and human hosts are usually males working in the forests clearing trees. In Africa, Aedes species not including A aegypti are implicated, whereas in South America, Haemagogus species are involved.

Urban cycle

The mosquito transmits the virus to a human host, from whom it is transmitted to another mosquito. In this cycle, which is confined to urban areas, A aegypti, a domestic mosquito that breeds in human-made containers, is the primary vector.

Intermediate (savannah) cycle

The mosquito transmits the virus to wild nonhuman primates and human hosts, and the virus is then transmitted to another mosquito. This cycle, confined to moist savannas and forest savanna ecotones of Africa, is the most common cycle for outbreaks in Africa. Many villages in a given area are affected simultaneously. Mortality appears to be lower with these outbreaks. Semidomestic mosquitoes that live in and outside of villages are the primary vectors.

This cycle may act as a bridge between the jungle and urban areas, leading to spread to urban centers, where an urban epidemic can result if contact is made between domestic mosquitoes and an unvaccinated human population.


In Africa, YF occurs in areas between 15° north and 10° south of the Equator, a region encompassing 34 countries with a total population of nearly 500 million people.[2] In South America and the Caribbean, enzootic countries include Bolivia, Brazil, British Guyana, Colombia, Ecuador, French Guyana, Panama (south of the Canal Zone), Peru, Surinam, Trinidad, and Venezuela. Human cases were reported in the 1990s in Bolivia, Brazil, Colombia, Ecuador, and Peru.

In Asia, although conditions currently exist for the transmission of YF in Asia (eg, on the Indian subcontinent), no documented transmission has ever occurred there. Evidence suggests that previous infection with another flavivirus (eg, those causing dengue) may confer protection from YF. This has been cited as the reason why YF has not been observed in Asia.

United States statistics

Since 1996, 3 fatal cases of YF have been reported in American travelers to the Amazon.[3, 4, 5] None of the patients were immunized against YF; 2 of them did receive other pretravel vaccinations, including the hepatitis A vaccine, but the third did not receive a medical consultation, YF vaccine, or malaria prophylaxis before traveling. Because patients with YF can present with a mild influenzalike illness, YF may not be recognized and may go unreported.

The outfitter of 1 of the patients stated, “The International medical community suggests yellow fever and malaria prophylaxis for the Amazon region. This is not a requirement to enter Brazil, but merely a suggestion.” The brochure of a travel agent stated, “We do not suggest any inoculations of any kind for this trip.... But to make sure you are worry free, consult with your personal physician.” These cases illustrate that some outfitters, travel agents, and physicians may underestimate health risks of travelers.[5]

In 1996, a 45-year-old man spent 9 days in the jungles of Brazil.[3] He returned to the United States with headache, myalgias, arthralgias, and chills. During an initial visit to an emergency department (ED), he had fever, leukopenia, thrombocytopenia, and mild elevations in hepatic transaminase values. He subsequently developed jaundice and hemorrhagic manifestations and died 10 days after developing symptoms. YF virus was isolated from tissue specimens.

In 1999, a 48-year-old man returned to the United States after a 10-day trip to a forested area of Venezuela.[4] During his trip, he received multiple mosquito bites. On the day of his return, he developed fever, chills, headache, photophobia, myalgias, arthralgias, nausea, vomiting, constipation, upper abdominal discomfort, and weakness. He developed hemorrhagic manifestations and died 9 days after developing symptoms. YF viral antigens were isolated from postmortem liver specimens by using immunohistochemical methods.

In 2002, a 47-year-old man traveled to the Brazilian Amazon to fish.[5] He slept in an air-conditioned boat and wore clothing impregnated with N,N -diethyl-m-toluamide (DEET). He returned to Texas and presented to an ED the same day, complaining of 4 days of crampy abdominal pain, 1 day of fever (102.8°F [39.3°C]), and severe headache. He was treated for presumed rickettsial infection and sent home.

Two days later, this patient was admitted for intractable vomiting. On initial evaluation, he had leukopenia (white blood cell [WBC] count 2.3 × 109/L [2300/µL]), coagulopathy, hepatic failure, and renal failure. He was treated for malaria. Bacterial cultures of blood, urine, and cerebrospinal fluid (CSF) were negative, as were malaria smears. On the fourth day, he developed shock and seizures. On the fifth day, he died.

Serum tests for immunoglobulin G (IgG) and immunoglobulin M (IgM) in this patient were negative for YF on days 2-7. Reverse-transcriptase polymerase chain reaction (PCR) assay of serum samples obtained on days 4, 5, and 7 and a postmortem liver specimen demonstrated YF virus RNA.

International statistics

Each year, an estimated 200,000 cases of YF occur in Africa and South America combined, causing an estimated 30,000 deaths. The number of total cases reported to the WHO each year from Africa and South America ranges from hundreds to a few thousand. The true incidence is estimated to be at least 40 times higher than the reported incidence in Africa and 10 times higher than the reported incidence in South America.[6]

Underreporting of YF occurs because many cases are mild or asymptomatic, because cases occur in remote regions, because populations are moving or displaced, or because the public health infrastructure is minimal or nonexistent (particularly in Africa, where regional conflicts are ongoing).

YF has been reemerging since 1980, with more cases being reported now than in the late 1940s. This trend is evident in Africa, where the number of countries reporting cases and the number of small-scale outbreaks have increased, where large populations are losing immunity (as a consequence of the end of mass-prevention campaigns in the early 1960s), and where vectors are present in urban areas.

In addition, African urban populations are markedly increasing by 4.8% per year), populations are migrating (either voluntarily or as a result of force), and vaccine often cannot be procured because of the expense.

In South America, A aegypti is now present in urban areas. This mosquito is the primary vector of urban YF, breeding in domestic and peridomestic containers. In the past 30 years, A aegypti has reinfested most of the countries from which it had previously been eradicated.

By 2008, A aegypti was present in the southern United States, Central America, the Caribbean, most major urban centers in tropical South America, the Indian subcontinent, Southeast Asia, Oceania, and northeast Australia. A legitimate concern is that YF could be reintroduced into these areas at any time because of global travel and trade and because of migrating populations. Nevertheless, YF has never been reported to be endemic to Asia.

The CDC estimates that YF immunization of travelers to YF-endemic areas declined 50% from 1992 to 1998. Travel to such areas poses a threat to the unimmunized traveler. Each year, an estimated 9 million travelers from North America, Europe, and Asia travel to endemic countries. At least one third of these travelers are exposed to areas where active transmission is known or unknown to be occurring.

Since 1979, at least 9 cases of traveler-related YF have been reported. Seven individuals, all unimmunized, died. Of the 2 survivors, 1 had been immunized. All traveled to rural areas, where no epidemics were known to be occurring.

The overall risk to an unimmunized traveler in Africa who is entering an area with epidemic activity is 1:267 for YF illness and 1:1333 for YF death during a 2-week trip. If the area is undergoing a silent period (ie, if existing surveillance methods do not detect active transmission), the risk is 1:2000 for YF illness and 1:10,000 for YF death for a 2-week trip. In South America, the risk is estimated to be one tenth as high.

In West Africa, the most dangerous time of year is between July and October; in Brazil, it is between January and March. In South America, Iguazú Falls on the Argentine-Brazil border is not considered a high-risk destination, but the risk is not zero either. For example, in 1996 and 2001, risk increased because of epizootic expansion. This example illustrates how the status of YF transmission in endemic countries is constantly shifting and unpredictable.

Reemergence in South America

YF is reemerging in South America. The following 3 factors are contributing to this reemergence:

  • Reinvasion of A aegypti since 1980 secondary to reductions in mosquito-control measures

  • Juxtaposition of areas of jungle transmission with areas of A aegypti infestation, allowing the latter to become reinfected

  • Lack of YF vaccination in densely populated areas outside of the traditional jungle transmission zone, creating huge populations at risk

Between 2007 and 2009, YF cases in South America were reported outside the usual areas of risk in Argentina, Brazil, and Paraguay.

In Argentina, 5 cases of jungle YF (with 1 death) were reported in Misiones Province. To contain this outbreak, more than 1.4 million people in Argentina have received YF vaccine (0.4 million in Misiones Province).

In Brazil, 45 cases of jungle YF were reported, with 25 deaths among 4 states. Parts of the states of Sao Paulo and Minas Gerais reported cases outside their usual risk areas, and the state of Espirito Santo, which is on the coast and is not a usual risk area at all, reported cases; however, as of late 2008, it is no longer considered a risk area.

In December 2008, Rio Grande do Sul, which is also outside the usual reporting area, reported 18 cases, including 7 deaths. Since February 2009, the state of Sao Paulo has reported 25 YF cases, including 9 deaths. To contain this outbreak, YF vaccinations have been increased in the reporting states and increased among travelers to these states, although YF vaccination coverage is already extensive.

In Paraguay, the first cases of YF in more than 30 years were reported in 2008 (25 cases, 8 deaths). These cases were mostly jungle YF but may have included urban YF; the city of San Lorenzo alone reported 9 cases with 3 deaths, YF cases occurred in 3 departments (San Pedro, Central, and Caaguazú). To contain this outbreak, more than 1.2 million people in 15 departments of Paraguay were given YF vaccine.

In Argentina and Brazil, the human outbreaks were preceded by weeks with an epizootic in monkeys.

Age-, sex-, and race-related differences in incidence

YF has no known age predilection. However, most infections in endemic countries occur in persons younger than 15 years because this group contains the largest population of nonimmune individuals. Occupational or recreational exposure may be increased among children as well.

No sex predilection is known. Because of occupational exposure, more men than women are infected in jungles and forests. No racial predilection is known.


Mortality from the toxic form of YF ranges from 25% to 50%, but the overall mortality has been reported to be as low as 1%. The number of reported deaths from YF among travelers over the past 10 years has increased, and more can be expected unless YF vaccine is most appropriately used.

If death does not occur, recovery without sequelae is the rule. Morbidity is minimal unless complications develop from the toxic form of the disease. Recovery from YF confers life-long immunity to reinfection.

Indicators of poor prognosis include the following:

  • Early onset of bilirubinemia

  • Marked albuminuria

  • Prothrombin time increased by more than 25%

  • Severe hemorrhage

  • Shock

  • Intractable hiccough (hiccup)

Patient Education

Increased public awareness of YF is important. All travelers going to YF-endemic areas (eg, destinations in the tropics or developing countries) should at least see a health provider who is familiar with traveler’s health recommendations from public health agencies. One source of such recommendations is the Traveler’s Health page of the CDC.

Even if the WHO does not have a requirement for YF vaccination for travel to a country, a traveler may still be exposed and concern may be warranted.




The clinical spectrum of yellow fever (YF) ranges from a minimally symptomatic flulike illness to a catastrophic illness complicated by hemorrhage and organ failure (primarily the liver and kidney). It develops in a number of distinct phases (not all of which invariably occur).

The incubation period typically lasts 3-6 days. No prodromal symptoms occur.

The infection period of infection lasts 3-4 days. Viremia is present. Susceptible biting mosquitoes can be infected with YF. Symptoms typically begin abruptly with fever, chills, malaise, prostration, headache, dizziness, myalgia (particularly lumbosacral area), anorexia, nausea, and vomiting.

The remission period lasts 2-24 hours. Symptoms and fever abate.

The abortive phase may extend over 1 day or longer. Recovery occurs without further symptoms.

The period of intoxication may last 3-5 days. Liver failure, hemorrhagic diathesis, and kidney failure occur. This period develops in approximately 15% of all cases. This stage is fatal in 1-50% of cases that develop toxicity. Previous symptoms and new symptoms include fever with high temperatures, chills, anxiety, confusion, lethargy, prostration, jaundice, epistaxis, anorexia, epigastric pain, nausea, vomiting, hematemesis, melena, lumbosacral pain, and decreased urine output. Complications include bacterial pneumonia and sepsis.

The period of convalescence may last days to weeks. The patient recovers completely, without sequelae. Complications may include protracted weakness and fatigability.

Physical Examination

The Pan American Health Organization has published a case definition for YF to aid in surveillance. By this definition, YF is an illness characterized by acute onset of fever followed by jaundice within 2 weeks of the onset of first symptoms plus 1 of the following:

  • Bleeding from the nose, gums, gastrointestinal (GI) tract, or skin

  • Death within 3 weeks of illness onset

A case of YF is classified as suspected if it meets the clinical definition or if other causes of fever or jaundice are excluded. A suspected YF case can be confirmed by laboratory testing or by being epidemiologically linked to a laboratory-confirmed case or outbreak.

Data to be reported to public health authorities include patient-specific identifier, age or date of birth, location, laboratory results, vaccination history, outcome of infection (alive, dead, unknown), case classification, and date of death (if dead).

Physical examination findings are nonspecific and may include the following:

  • Fever

  • Pulse - Slow, inversely proportional to temperature (Faget sign)

  • Anxiety, lethargy, prostration, confusion, coma

  • Facies - Flushed

  • Conjunctival injection

  • Abdominal tenderness

  • Hemorrhagic manifestations - Epistaxis, gingival bleeding, hematosis, melena, hematuria

  • Urine output - Decreased

  • Shock


Complications of YF include the following:

  • Organ failure - Liver (secondary to hepatic necrosis), kidney (secondary to parenchymal injury and acute tubular necrosis), heart (secondary to parenchymal injury)

  • Hemorrhagic diathesis - YF virus directly injures the liver, kidney, and heart; a hemorrhagic diathesis progressing to disseminated intravascular coagulation (DIC) is not uncommon in the toxic form of the disease, because of hepatic damage, thrombocytopenia, and perhaps other factors

  • Secondary infections, particularly bacterial pneumonia



Diagnostic Considerations

In addition to the conditions listed in the differential diagnosis, other problems to be considered include the following:

  • Arboviral infections - Lassa fever, chikungunya, dengue

  • Carbon tetrachloride poisoning

  • Influenza

  • Hepatitis E

  • Sepsis

  • Typhoid fever

  • West Nile virus infection (with hepatitis)

Differential Diagnoses



Approach Considerations

The diagnosis of yellow fever (YF) is made on the basis of any 1 of the following:

  • Isolation of YF virus

  • Isolation of YF virus–specific immunoglobulin M (IgM)

  • Fourfold or greater rise in serum immunoglobulin G (IgG)

  • Positive findings on postmortem liver histopathology

  • Detection of YF antigen in tissues with immunohistochemistry

  • Detection of YF viral genomic sequences with polymerase chain reaction (PCR) evaluation

For guidance on specimen collection and detection of yellow fever virus, contact the Centers for Disease Control and Prevention (CDC).

Laboratory Studies

A complete blood count (CBC) is indicated. Leukopenia with neutropenia may be observed during the initial stage of yellow fever infection. Thrombocytopenia may be observed during the toxic stage of yellow fever infection.

Electrolyte, blood urea nitrogen (BUN), creatinine, and glucose levels should be measured. Results may reveal azotemia. Hypoglycemia may occur because of a lack of oral intake and hepatic dysfunction. Hyperkalemia may be secondary to renal dysfunction.

Liver function tests typically reveal elevated transaminase and bilirubin levels during the toxic stage of illness. Transaminase levels may remain elevated for as long as 2 months after recovery.

On coagulation studies, an abnormal pattern resembling disseminated intravascular coagulation (DIC) may occur during the toxic stage of illness.

Urinalysis often reveals clinically significant proteinuria. Blood, urine, and cerebrospinal fluid (CSF) cultures should be performed to exclude other infections. CSF findings may be typical of yellow fever, with increased pressure, elevated protein levels, cell counts in the reference range, or pleocytosis.

Malaria smears may be helpful. Findings may exclude concurrent malaria. Thick smears are needed to diagnose malaria. Thin smears are used to speciate the parasite.

Samples of acute and convalescent sera should be obtained for viral isolation and diagnosis. Send the samples to the CDC National Center for Infectious Diseases, Division of Vector-Borne Infectious Diseases.

Imaging and Electrocardiography

In general, no specific imaging studies are indicated for the diagnosis and management of YF. Use imaging to diagnose other primary or secondary conditions.

Chest radiography is important early in the course of YF to diagnose primary infection. It is indicated to exclude pneumonia in a patient whose condition deteriorates.

Electrocardiography (ECG) may show nonspecific ST-segment and T-wave changes. It may also show arrhythmias.


Peripheral intravenous (IV) may be done for hydration and administration of medications, including antibiotics as needed.

Central venous catheterization may be done to achieve hydration and to monitor central venous pressure in critically ill patients.

Arterial catheterization may be done to monitor blood pressure in patients who are critically ill and to provide serial measurements of blood gas values.

Bladder catheterization may be done to monitor urine output and to monitor renal function (particularly for proteinuria).

Histologic Findings

YF virus is viscerotropic. Histologic assessment of infected liver tissue may reveal initial infection of the Kupffer cells, followed by coagulation necrosis of the midzone (zone 2) hepatocytes, which spares zones adjacent to the central vein and portal triad. Intracellular hyaline deposits (Councilman bodies) are present with eosinophilic degeneration of hepatocytes, Torres bodies, intranuclear inclusions, microvesicular fat accumulation, deposition of eosinophilic pigment, and minimal mononuclear inflammatory infiltrate.

Recovery leads to complete healing without cirrhosis. When renal involvement occurs, the kidney is generally edematous, and the cells of the tubular epithelium and glomerular endothelium are swollen. Mesangial proliferation occurs. Viral antigen is found in the glomeruli and tubules. Acute tubular necrosis occurs secondary to circulatory collapse. Heart tissue may demonstrate myocardial cell degeneration and fatty infiltration.



Approach Considerations

No specific treatment for yellow fever (YF) is noted. Supportive care is the mainstay of management. Base management decisions on the presence of dehydration, electrolyte imbalance, organ failure, concurrent infections, secondary infections, hemorrhagic diathesis, and generalized symptoms. The managing physician must be thoroughly versed in critical care management to coordinate the various interventions to the maximum benefit of the patient.

Patients who recover do so with minimal end-organ damage. In addition, they develop life-long immunity from further infection with YF virus.

Supportive Care

Monitor fluid status, and hydrate to maintain organ perfusion. Monitor electrolyte status, and promptly correct any abnormalities.

Monitor and be prepared to manage organ failure secondary to direct organ injury from YF virus that leads to cardiogenic shock, hepatic coma, and renal failure necessitating dialysis.

Monitor the coagulation profile, and correct any abnormalities. Blood products may be required. Anticipate possible disseminated intravascular coagulation (DIC). Also anticipate possible secondary bacterial infections, particularly pneumonia. Exclude concurrent malaria.

If the necessary clinical expertise, monitoring capability, and treatment modalities necessary for managing YF are not available at the current institution, transfer the patient to another institution. Ensure that the patient is stable enough for transfer.

Physicians with experience in pediatric medicine, infectious or tropical diseases, pediatric critical care, and nephrology should be readily available at the institution to which the patient is being transferred. An attending physician at that institution must accept the patient in transfer.

The recommended diet and level of activity are based on the patient’s general status, the presence of any organ failure, and the development of a hemorrhagic diathesis.


Prevention remains the cornerstone to minimizing the risk of yellow fever. Travelers to endemic areas and local populations should be vaccinated. The currently available vaccine confers near lifelong immunity in 95% of patients.[7, 8]

A single, lifetime dose of yellow fever vaccine is sufficient for most people traveling to endemic areas according to the CDC's Advisory Committee on Immunization Practices and the World Health Organization. The CDC also recommends that some high-risk groups may receive a booster dose after 10 years or an additional dose before traveling to an endemic area.[9, 10]

Due to a shortage of yellow fever vaccine (YF-VAX) in 2017, Stamaril yellow fever vaccine is being imported into the United States. Providers should be aware of the vaccine shortage.[11, 12]  

An additional dose is recommended for the following populations:

  • Women who were pregnant (regardless of trimester) when they received their initial dose of yellow fever vaccine should receive 1 additional dose before their next travel that puts them at risk for yellow fever virus infection
  • Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated before their next travel that puts them at risk for yellow fever virus infection

A booster dose is recommended for the following high risk populations after 10 years:

  • A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 y previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel  (bullet) Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 y
  • Travelers who plan to spend a prolonged period in endemic areas or those traveling to highly endemic areas such as rural West Africa during peak transmission season or an area with an ongoing outbreak
  • Laboratory workers who routinely handle wild-type yellow fever virus should have yellow fever virus–specific neutralizing antibody titers measured at least every 10 y to determine if they should receive additional doses of the vaccine
  • For laboratory workers who are unable to have neutralizing antibody titers measured, yellow fever vaccine should be given every 10 y as long as they remain at risk


Medication Summary

No specific medication is indicated in the treatment of yellow fever (YF). Medication selection is based on the control of symptoms, secondary infections, and organ failure. Antipyretics may have limited use if no hepatic or renal compromise is noted.

In addition, comorbid conditions may occur that require medication, and the risks and benefits of such medications must be considered before they are continued during the acute phase of illness.

Analgesic and antipyretic agents

Class Summary

Antipyretics should be used only with caution, if at all, because of their metabolic effects on the liver and kidney. Do not use acetaminophen in the presence of hepatic compromise. Do not use ibuprofen in the presence of hepatic or renal compromise.

Acetaminophen (Tylenol, Feverall, Triaminic Children's Fever, Mapap)

Ibuprofen (Advil, Motrin, Neoprofen)

Ibuprofen is the drug of choice for mild-to-moderate pain; it is also used to reduce fever. It inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Vaccines, Live, Viral

Class Summary

Active immunization increases resistance to infection. Vaccines consist of microorganisms or cellular components, which act as antigens. Administration of the vaccine stimulates the production of antibodies with specific protective properties.

Yellow fever vaccine (YF-Vax)

The YF vaccine is a live attenuated virus preparation prepared by culturing 17D-strain YF virus in living chick embryo. Immunity may start 7-10 days after vaccination. The World Health Organization (WHO) requires revaccination every 10 years to maintain travelers' vaccination certificates; in the United States, these which are valid for 10 years, beginning 10 days after initial vaccination or revaccination.